- Axios reported that top pharmaceutical companies have announced significant so called ‘buybacks,’ which benefit shareholders by driving up the value of their stock.
- Contributions to Republican Party have yielded a great ROI for pharma.
- This suggests that pharmaceutical companies have used these tax breaks to enrich investors, a decision that comes at the expense of lowering the price of prescription drugs, investing in research and development that could lead to new cures, or passing along savings to consumers.”
KEY TAKEAWAY: Wells Fargo on pharma: “We get the impression that many in the industry and many investors do not see the trouble brewing. We worry that some may be living in a bubble, a cozy patent-protected, high margin bubble.” Continue reading
KEY TAKEAWAY: According to numerous consulting reports I’ve read one of the biggest obstacles to big pharma is the organization itself. Over the years I have asked the employees of biopharma companies what they really think needs to change. Here are some of the top wishes.. Continue reading
KEY TAKEAWAY: The pharma industry has helped a lot of people live longer, more productive lives, but the industry also has a lot of self caused problems from high drug prices and outrageous CEO pay to a blazing lack of transparency. Rather than acknowledge and write about these issues the trade press seems to only praise and write articles from press releases. Continue reading
KEY TAKEAWAY: Talk to anyone within pharma and you’re likely to find that their calendar is filled with meetings. Even medical people are often pulled from the field to attend costly training meetings that waste time and money. Why haven’t pharma companies used online training more to help reduce expenses? Continue reading
KEY TAKEAWAY: Organizations have to adapt to meet the new challenges in the marketplace, but pharma companies pretty much do business the same way since the turn of the century. Bigger is not better and matrix management can only add needless time and waste resources. Continue reading
KEY TAKEAWAY: GSK and Novartis are just two pharma companies that have indicated they are cutting budgets at a time when healthcare is going through an enormous disruption. Will these cuts limit DTC’s ability to evolve to meet the needs of the connected patients? Continue reading